Literature DB >> 1360207

The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin.

I A de Lannoy1, M Silverman.   

Abstract

Digoxin, a widely used cardiac glycoside with a low therapeutic index, is known to interact with a large and diverse group of co-administered drugs, frequently leading to toxic accumulation of the glycoside. Establishing the mechanism(s) of these interactions, therefore, has potential clinical significance. The present studies implicate P-glycoprotein, the MDR1 gene product overexpressed in multidrug resistant cells, as the apical membrane protein responsible for the renal secretion of digoxin and provide an explanation for the occurrence of digoxin toxicity in the presence of certain co-administered medications. Since digoxin is considered a prototype for endogenous digitalis-like glycosides, the results also allow for speculation that endogenous digitalis-like glycosides may be the natural substrates for P-gp.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1360207     DOI: 10.1016/0006-291x(92)91593-f

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  39 in total

1.  Identifying candidate causal variants responsible for altered activity of the ABCB1 multidrug resistance gene.

Authors:  Nicole Soranzo; Gianpiero L Cavalleri; Michael E Weale; Nicholas W Wood; Chantal Depondt; Richard Marguerie; Sanjay M Sisodiya; David B Goldstein
Journal:  Genome Res       Date:  2004-06-14       Impact factor: 9.043

2.  Marinobufagenin enhances cardiac contractility in mice with ouabain-sensitive alpha1 Na+-K+-ATPase.

Authors:  Arshani N Wansapura; Valerie Lasko; Zijian Xie; Olga V Fedorova; Alexei Y Bagrov; Jerry B Lingrel; John N Lorenz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-04-17       Impact factor: 4.733

3.  Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein.

Authors:  U Mayer; E Wagenaar; J H Beijnen; J W Smit; D K Meijer; J van Asperen; P Borst; A H Schinkel
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

4.  Using Physiologically Based Pharmacokinetic (PBPK) Modeling to Evaluate the Impact of Pharmaceutical Excipients on Oral Drug Absorption: Sensitivity Analyses.

Authors:  Edwin Chiu Yuen Chow; Arjang Talattof; Eleftheria Tsakalozou; Jianghong Fan; Liang Zhao; Xinyuan Zhang
Journal:  AAPS J       Date:  2016-08-12       Impact factor: 4.009

Review 5.  Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation.

Authors:  Joseph D Ma; Shirley M Tsunoda; Joseph S Bertino; Meghana Trivedi; Keola K Beale; Anne N Nafziger
Journal:  Clin Pharmacokinet       Date:  2010-04       Impact factor: 6.447

6.  Exposure-response relationships and drug interactions of sirolimus.

Authors:  James J Zimmerman
Journal:  AAPS J       Date:  2004-10-15       Impact factor: 4.009

Review 7.  Differential pharmacokinetics of digoxin in elderly patients.

Authors:  C G Hanratty; P McGlinchey; G D Johnston; A P Passmore
Journal:  Drugs Aging       Date:  2000-11       Impact factor: 3.923

8.  Increased absorption of digoxin from the human jejunum due to inhibition of intestinal transporter-mediated efflux.

Authors:  Svitlana Igel; Siegfried Drescher; Thomas Mürdter; Ute Hofmann; Georg Heinkele; Heike Tegude; Hartmut Glaeser; Stefanie S Brenner; Andrew A Somogyi; Taher Omari; Christian Schäfer; Michel Eichelbaum; Martin F Fromm
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 9.  Pharmacokinetic interactions with rifampicin : clinical relevance.

Authors:  Mikko Niemi; Janne T Backman; Martin F Fromm; Pertti J Neuvonen; Kari T Kivistö
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

10.  pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions.

Authors:  Sibylle Neuhoff; Anna-Lena Ungell; Ismael Zamora; Per Artursson
Journal:  Pharm Res       Date:  2003-08       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.